Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
GPTRF$0.19-0.01(-5.14%)Grande Portage Resources Ltd. to Attend the 52nd Annual New Orleans Investment Conference[12:14:00 PM ET]ORCL$131.70+5.64(+4.47%)Oracle Reinvents Enterprise Computing for the AI Era with OpenAI Oracle AI World -- Oracle today announced a major new collaboration with OpenAI to redefine how the world's businesses run in the age of AI. By...[12:08:00 PM ET]ORCL$131.70+5.64(+4.47%)Oracle Brings Google TPUs to Oracle Cloud Infrastructure Oracle AI World -- Oracle and Google today announced that Google's Tensor Processing Units (TPUs) will be available through Oracle Cloud...[12:07:00 PM ET]SMP$37.43+0.15(+0.40%)Standard Motor Products, Inc. Announces Third Quarter 2026 Earnings Conference Call Standard Motor Products, Inc. (NYSE: SMP), a leading automotive parts manufacturer and distributor, is scheduled to report its earnings for the three ...[12:06:00 PM ET]SNOW$340.23+5.28(+1.57%)Oracle Expands Native AI and Data Services on OCI with Snowflake Oracle AI World -- Oracle and Snowflake (NYSE: SNOW) today announced that Snowflake AI Data Cloud will be available as a native, first-party service...[12:06:00 PM ET]ORCL$131.70+5.64(+4.47%)Oracle Advances Enterprise Security for the AI Era Oracle AI World -- Oracle today announced Oracle AI Security Mesh, powered by OpenAI. The new offering complements Oracle Cloud Infrastructure (OCI)...[12:05:00 PM ET]ORCL$131.70+5.64(+4.47%)Oracle Introduces Oracle Media Fabric Oracle AI World -- Oracle today announced Oracle Media Fabric, an integrated platform designed to help media companies, streaming providers, and...[12:04:00 PM ET]ORCL$131.70+5.64(+4.47%)Oracle Unveils New Cloud Networking Innovations for AI Oracle AI World -- Oracle today announced new capabilities in Oracle Acceleron, Oracle Cloud Infrastructure's (OCI) suite of networking and...[12:03:00 PM ET]ADT$6.89+0.00(+0.07%)ADT Secures AI Innovation with Oracle Oracle AI World -- ADT Inc. (NYSE: ADT), the trusted leader in smart home security solutions, is expanding its use of AI with Oracle AI...[12:02:00 PM ET]ORCL$131.70+5.64(+4.47%)Oracle Expands Fusion Data Intelligence with New Deep Insight Agents, Operational Analytics, and AI Capabilities Oracle AI World -- Oracle today announced new Oracle Fusion Data Intelligence capabilities that help customers uncover insights closer to the...[12:01:00 PM ET]WDFN$38.500.00(0.00%)Woodlands Financial Services Company Announces Fourth Quarter Cash Dividend[12:00:00 PM ET]CBRS$117.97+9.60(+8.86%)Cerebras and Oracle Team Up to Bring Cerebras AI Inference to Oracle Cloud Infrastructure[12:00:00 PM ET]IVZ$28.95+0.41(+1.45%)Invesco Announces Work with Anthropic to Bring its Custom Portfolio and Practice Management Capabilities to Claude Invesco Ltd. (NYSE: IVZ), a leading global asset management firm, announced today it is working with Anthropic to bring its data to support portfolio ...[12:00:00 PM ET]MSGM$4.47-0.17(-3.56%)Motorsport Games' Proprietary RaceControl Platform Powers Record Concurrent Players for Le Mans Ultimate in Biggest 24 Hours of Le Mans Online Event Yet[12:00:00 PM ET]ORCL$131.70+5.64(+4.47%)Oracle AI Data Platform Brings AI-Assisted Business Context to Enterprise AI Oracle AI World -- Oracle today announced new Oracle AI Data Platform capabilities that help customers build, deploy, and scale enterprise AI by...[12:00:00 PM ET]NVDA$218.71+2.71(+1.25%)NVIDIA and Oracle Expand NVIDIA Vera Rubin to Multi-Gigawatt Scale and Bring NVIDIA Vera CPU to Oracle Cloud Infrastructure[12:00:00 PM ET]

MIRM · NASDAQ

Mirum Pharmaceuticals, Inc.

$83.81 +0.55 (+0.66%)

Company overview

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for Alagille syndrome and biliary atresia disease. It also develops volixibat for the treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$5.4B
Employees
334
Headquarters
Foster City, CA
Website
mirumpharma.com
CEO
Christopher Peetz
Listed
July 18, 2019
P/E
-6.16
Dividend yield
0.00%

Company financials

Revenue
$570M
Gross profit
$463M
Operating income
-$70.1M
EBITDA
-$38.3M
Net income
-$799M
EPS
-$13.61
Total assets
$891M
Total debt
$324M
Gross margin
81.36%
Net margin
-140.24%
Earnings yield
-16.22%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

75.6989.79103.89117.99132.09
MIRM 1D NASDAQ O81.40H83.39L81.28C83.26+2.87 (+3.57%)Vol87.65K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks Investment Research
MIRMMirum Pharmaceuticals, Inc. Stock news Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM) Defense World
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases Zacks Investment Research
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript Seeking Alpha
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases MarketBeat
MIRMMirum Pharmaceuticals, Inc. Press release Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Business Wire
MIRMMirum Pharmaceuticals, Inc. Press release Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Business Wire
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study MarketBeat
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV Zacks Investment Research
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript Seeking Alpha
MIRMMirum Pharmaceuticals, Inc. Stock news MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy Zacks Investment Research
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum's liver infection drug lowers virus levels in late-stage study Reuters
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus Business Wire
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 GuruFocus
MIRMMirum Pharmaceuticals, Inc. Press release Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 Business Wire
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Average Target Price of $137.31 Defense World
MIRMMirum Pharmaceuticals, Inc. Stock news US FDA approves Mirum's drug for rare bone disorder Reuters
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events Seeking Alpha
MIRMMirum Pharmaceuticals, Inc. Stock news Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
See more
FAQ

Questions about Mirum Pharmaceuticals, Inc.

What does Mirum Pharmaceuticals, Inc. do?
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for Alagille syndrome and biliary atresia disease. It also develops volixibat for the treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
What is MIRM's market cap?
Mirum Pharmaceuticals, Inc. (MIRM) is a listed stock with a live quote. The latest market cap on this page is $5.4B.
Where is Mirum Pharmaceuticals, Inc. headquartered?
Mirum Pharmaceuticals, Inc. is headquartered in Foster City, CA.
How do I get MIRM news from the API?
Call GET /v1/news?tickers=MIRM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does MIRM news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MIRM, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the MIRM price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs